PIK3CA mutations occur in about 15%–20% of colorectal cancer cases and are often associated with resistance to some types of chemotherapy and anti-EGFR therapy (Voutsadakis, 2021; Voutsadakis, 2023). Here, EGFR is linked to colorectal cancer.